Skip to content

Study · Non-randomized trial · n = 6 · 1992

5 results

Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.

Clemmons DR, Smith-Banks A, Underwood LE

The Journal of clinical endocrinology and metabolism1 Jul 1992Cited by 86 (Europe PMC)

PMID1619015 (opens in a new tab)DOI10.1210/jcem.75.1.1619015 (opens in a new tab)PepBankPUB-01619015
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    IGF-I improved nitrogen balance versus diet alone in calorie-restricted young adults.

    In plain wordsIn calorie-restricted young adults, IGF-I improved nitrogen balance compared with diet alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseNitrogen balance versus diet alone
    Study

    n = 6

    Comparator
    Diet alone
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    12 micrograms/kg/h over 16 h · intravenous infusion · 6 daysAs given in this study (human).

    Measurements

    Nitrogen balance
    −236 mmol/day
    diet alone (SE 45)
    Nitrogen balance
    −65 mmol/day
    last 4 days of IGF-I infusion (SE 40)
    P value for nitrogen balance
    < 0.001 dimensionless
    Diet alone versus last 4 days of IGF-I infusion

    Source sentences

    Summary
    IGF-I improved nitrogen balance from -236 +/- 45 mmol/day (+/- SE) during diet alone, to -65 +/- 40 mmol/day (P less than 0.001) during the last 4 days of IGF-I infusion.
    2 context sentences
    Summary · context
    A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day.
    Summary · context
    During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection).
  2. 02HumanNon-randomized trialEfficacy outcome

    IGF-I and GH similarly reduced nitrogen wasting in magnitude and timing in calorie-restricted young adults.

    In plain wordsIn calorie-restricted young adults, IGF-I and growth hormone reduced nitrogen loss similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeNitrogen wasting versus GH
    Study

    n = 6

    Comparator
    GH
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    12 micrograms/kg/h over 16 h · intravenous infusion · 6 daysAs given in this study (human).

    Source sentences

    Summary
    At the dose of each hormone used, the attenuation of nitrogen wasting produced by infusions of IGF-I was similar in magnitude and timing to that produced by injections of GH.
    2 context sentences
    Summary · context
    A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day.
    Summary · context
    During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection).
  3. 03HumanNon-randomized trialEfficacy outcome

    IGF-I reduced fasting blood glucose versus diet alone in calorie-restricted young adults.

    In plain wordsIn calorie-restricted young adults, IGF-I reduced fasting blood sugar compared with diet alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseFasting glucose versus diet alone
    Study

    n = 6

    Comparator
    Diet alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12 micrograms/kg/h over 16 h · intravenous infusion · 6 daysAs given in this study (human).

    Measurements

    Fasting blood glucose
    4.94 mmol/L
    diet alone
    Fasting blood glucose
    3.13 mmol/L
    during IGF-I infusion
    Fasting blood glucose reported +/- uncertainty (type not stated)
    0.91 mmol/L
    diet alone
    Fasting blood glucose reported +/- uncertainty (type not stated)
    0.44 mmol/L
    during IGF-I infusion
    P value for fasting blood glucose
    < 0.001 dimensionless
    Diet alone versus IGF-I infusion

    Source sentences

    Summary
    IGF-I infusion decreased fasting blood glucose from 4.94 +/- 0.91 mmol/L to 3.13 +/- 0.44 mmol/L (P less than 0.001), while GH raised blood glucose values (4.75 +/- 1.01 mmol/L on diet alone, to 5.48 +/- 1.00 during the period of GH treatment; P less than 0.05).
    2 context sentences
    Summary · context
    A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day.
    Summary · context
    During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection).
  4. 04HumanNon-randomized trialEfficacy outcome

    IGF-I reduced serum insulin versus diet alone in calorie-restricted young adults.

    In plain wordsIn calorie-restricted young adults, IGF-I reduced insulin compared with diet alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseInsulin versus diet alone
    Study

    n = 6

    Comparator
    Diet alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12 micrograms/kg/h over 16 h · intravenous infusion · 6 daysAs given in this study (human).

    Measurements

    Serum insulin
    74.9 pmol/L
    diet alone
    Serum insulin
    16.7 pmol/L
    during IGF-I infusion
    Serum insulin reported +/- uncertainty (type not stated)
    26.8 pmol/L
    diet alone
    Serum insulin reported +/- uncertainty (type not stated)
    1.5 pmol/L
    during IGF-I infusion

    Source sentences

    Summary
    Despite these differences in blood glucose, IGF-I infusions decreased serum insulin (74.9 +/- 26.8 pmol/L on diet alone, to 16.7 +/- 1.5 pmol/L during IGF-I)
    2 context sentences
    Summary · context
    A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day.
    Summary · context
    During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection).
  5. 05HumanNon-randomized trialEfficacy outcome

    IGF-I reduced serum connecting peptide versus diet alone in calorie-restricted young adults.

    In plain wordsIn calorie-restricted young adults, IGF-I reduced connecting peptide compared with diet alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseConnecting peptide versus diet alone
    Study

    n = 6

    Comparator
    Diet alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12 micrograms/kg/h over 16 h · intravenous infusion · 6 daysAs given in this study (human).

    Measurements

    Serum connecting-peptide
    2.14 mmol/L
    diet alone
    Serum connecting-peptide
    0.97 mmol/L
    during IGF-I infusion
    Serum connecting-peptide reported +/- uncertainty (type not stated)
    0.89 mmol/L
    diet alone
    Serum connecting-peptide reported +/- uncertainty (type not stated)
    0.14 mmol/L
    during IGF-I infusion

    Source sentences

    Summary
    and serum connecting-peptide concentrations (2.14 +/- 0.89 mmol/L on diet alone, to 0.97 +/- 0.14 during IGF-I)
    2 context sentences
    Summary · context
    A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day.
    Summary · context
    During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.